Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Expression of Nigrostriatal α6-Containing Nicotinic Acetylcholine Receptors Is Selectively Reduced, but Not Eliminated, by β3 Subunit Gene Deletion

Cecilia Gotti, Milena Moretti, Francesco Clementi, Loredana Riganti, J. Michael McIntosh, Allan C. Collins, Michael J. Marks and Paul Whiteaker
Molecular Pharmacology June 2005, 67 (6) 2007-2015; DOI: https://doi.org/10.1124/mol.105.011940
Cecilia Gotti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milena Moretti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Clementi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loredana Riganti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Michael McIntosh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan C. Collins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Marks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Whiteaker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

mRNAs for the neuronal nicotinic acetylcholine receptor (nAChR) α6 and β3 subunits are abundantly expressed and colocalized in dopaminergic cells of the substantia nigra and ventral tegmental area. Studies using subunit-null mutant mice have shown that α6- or β3-dependent nAChRs bind α-conotoxin MII (α-CtxMII) with high affinity and modulate striatal dopamine release. This study explores the effects of β3 subunit-null mutation on striatal and midbrain nAChR expression, composition, and pharmacology. Ligand binding and immunoprecipitation experiments using subunit-specific antibodies indicated that β3-null mutation selectively reduced striatal α6* nAChR expression by 76% versus β3+/+ control. Parallel experiments showed a smaller reduction in both midbrain α3* and α6* nAChRs (34 and 42% versus β3+/+ control, respectively). Sedimentation coefficient determinations indicated that residual α6* nAChRs in β3–/– striatum were pentameric, like their wild-type counterparts. Immunoprecipitation experiments on immunopurified β3* nAChRs demonstrated that almost all wild-type striatal β3* nAChRs also contain α4, α6, and β2 subunits, although a small population of non-β3 α6* nAChRs is also expressed. β3 subunit incorporation seemed to increase α4 participation in α6β2* complexes. 125I-Epibatidine competition binding studies showed that the α-CtxMII affinity of α6* nAChRs from the striata of β3–/– mice was similar to those isolated from β3+/+ animals. Together, the results of these experiments show that the β3 subunit is important for the correct assembly, stability and/or transport of α6* nAChRs in dopaminergic neurons and influences their subunit composition. However, β3 subunit expression is not essential for the expression of α6*, high-affinity α-CtxMII binding nAChRs.

  • Received February 9, 2005.
  • Accepted March 4, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 67 (6)
Molecular Pharmacology
Vol. 67, Issue 6
1 Jun 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Expression of Nigrostriatal α6-Containing Nicotinic Acetylcholine Receptors Is Selectively Reduced, but Not Eliminated, by β3 Subunit Gene Deletion
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Expression of Nigrostriatal α6-Containing Nicotinic Acetylcholine Receptors Is Selectively Reduced, but Not Eliminated, by β3 Subunit Gene Deletion

Cecilia Gotti, Milena Moretti, Francesco Clementi, Loredana Riganti, J. Michael McIntosh, Allan C. Collins, Michael J. Marks and Paul Whiteaker
Molecular Pharmacology June 1, 2005, 67 (6) 2007-2015; DOI: https://doi.org/10.1124/mol.105.011940

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Expression of Nigrostriatal α6-Containing Nicotinic Acetylcholine Receptors Is Selectively Reduced, but Not Eliminated, by β3 Subunit Gene Deletion

Cecilia Gotti, Milena Moretti, Francesco Clementi, Loredana Riganti, J. Michael McIntosh, Allan C. Collins, Michael J. Marks and Paul Whiteaker
Molecular Pharmacology June 1, 2005, 67 (6) 2007-2015; DOI: https://doi.org/10.1124/mol.105.011940
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Nelfinavir and PXR
  • P2X7 Positive Modulator Structure-Activity Relationship
  • Predicting Drug Interactions with ENT1 and ENT2
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics